PFE - Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo Eli Shares | Benzinga
Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss solutions.
Reporting on Feb. 6, Eli Lilly is expected to post quarterly earnings of $2.76 per share, up 32.1% from the same period a year ago. Revenue for the quarter is expected to climb 21.4% to $8.86 billion, according to Zacks consensus estimates.
On Wednesday, Eli Lilly’s chief rival in the weight-loss treatment market Novo Nordisk beat earnings estimates of $0.65 a share with its fourth quarter result of $0.71 and also topped revenue expectations, according to Benzinga Pro data.
Also Read: Could IBM’s Return To Office ‘Or Else’ Be Code For Poor Performance?
Shares Have Soared In 2023
Both companies are trading at, or close to, record highs and have seen their market capitalizations double in the ...